ELEKTA AB/ADR (EKTAY) Downgraded by Zacks Investment Research to Sell

Share on StockTwits

Zacks Investment Research cut shares of ELEKTA AB/ADR (OTCMKTS:EKTAY) from a hold rating to a sell rating in a research report sent to investors on Monday, Zacks.com reports.

According to Zacks, “Elekta AB is a human care company engaged in developing and selling clinical solutions for the treatment of cancer and neurological diseases. It develops tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. The Company’s offering is divided into five areas: Neuroscience, Oncology, Software, Brachytherapy and Services. Elekta AB is headquartered in Stockholm, Sweden. “

Separately, ValuEngine downgraded ELEKTA AB/ADR from a buy rating to a hold rating in a research report on Tuesday, April 9th.

EKTAY stock opened at $11.41 on Monday. The firm has a market cap of $4.20 billion, a PE ratio of 32.59, a PEG ratio of 2.70 and a beta of 0.52. ELEKTA AB/ADR has a twelve month low of $10.96 and a twelve month high of $14.61. The company has a quick ratio of 0.93, a current ratio of 1.18 and a debt-to-equity ratio of 0.62.

ELEKTA AB/ADR (OTCMKTS:EKTAY) last released its earnings results on Friday, February 22nd. The company reported $0.06 earnings per share for the quarter. The company had revenue of $367.04 million during the quarter. ELEKTA AB/ADR had a return on equity of 16.86% and a net margin of 9.35%. On average, equities research analysts predict that ELEKTA AB/ADR will post 0.35 earnings per share for the current fiscal year.

ELEKTA AB/ADR Company Profile

Elekta AB (publ) provides equipment and software for cancer and brain disorders worldwide. The company offers radiotherapy systems under the Versa HD, Precise Treatment System, and Elekta Compact names; Elekta Infinity, an image-guided radiation therapy (IGRT) system; and Elekta Synergy, a digital accelerator for advanced IGRT.

Featured Story: Moving Average Convergence Divergence (MACD)

Get a free copy of the Zacks research report on ELEKTA AB/ADR (EKTAY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ELEKTA AB/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ELEKTA AB/ADR and related companies with MarketBeat.com's FREE daily email newsletter.